Even Apolo Ohno gets sick. Vicks incorporated a celebrity in their current “better looking tomorrow” campaign.

Click here to see other executions from this campaign.

This ad and thousands more can be seen on the AdPharm gallery, the largest online pharmaceutical advertising gallery.

Click here to see the original post on AdPharm

Visit AdPharm.net for more pharmaceutical ads

What could you do with 15 letters?
Show her the world.

Give your patients a chance to gain as many lines as possible.

Lucentis is the first and only therapy proven to deliver a 3-line gain in up to 41% of patients at 2 years with monthly dosing (vs 4% with sham and 6% withverteporfin PDT)

Nearly all Lucentis-treated patients – 90% – maintained vision at 2 years (vs 53% with sham and 66% with verteporfin PDT)

Brand name: Lucentis
Generic name/category: Ranibizumab, Ophtalmology
Company: Genentech
Country/Market: USA, North America
Indication(s)/use: neovascular (wet) age-related macular degeneration
Target: Healthcare Professionals (HCP)
Tagline: Lines gained. Lives changed.
Publication: Ophtalmology Times June 2009

To see all of this brand’s ads on AdPharm, click here